XML 70 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions, Research Collaborations and Licensing Agreements (Tables)
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:
November 19, 2021
Cash and cash equivalents$340 
Investments285 
Identifiable intangible assets: (1)
IPR&D - sotatercept 6,380 
Product rights - Reblozyl (12 year useful life)
3,830 
Deferred income tax liabilities, net(1,814)
Other assets and liabilities, net82 
Total identifiable net assets9,103 
Goodwill (2)
2,411 
Consideration transferred$11,514 
(1)    The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.